"GST reduction makes diagnostics more accessible and supports “Make in India” vision by levelling the field for local products"
BioSpectrum Asia
|BioSpectrum Asia Nov 2025
The Association of Diagnostics Manufacturers of India (ADMI), the apex body representing 80-90 domestic and multinational in vitro diagnostics (IVD) companies, has announced the election of Jatin Mahajan, Managing Director of J. Mitra & Co., as its new President recently. Under his leadership, ADMI aims to foster greater collaboration between Indian firms and global players through inclusive working groups and open forums. By presenting a unified industry voice, the association plans to engage policymakers and regulators more effectively, advocating for regulatory reforms, quality standards, tax rationalization, and other supportive policies. In an interaction with BioSpectrum Asia Mahajan emphasizes that aligning perspectives across the sector will not only ensure a level playing field but also drive sustainable growth, strengthen India's diagnostics ecosystem, and enhance its global competitiveness. Edited excerpts;
Being the newly appointed president of the ADMI, how do you foresee the future of India's diagnostic sector?
I am optimistic about the future of India's diagnostic sector. We're at a juncture where diagnostics are rightly being recognised as a cornerstone of healthcare. In the coming years, I see India becoming a global hub for affordable, high-quality diagnostics. Our industry is growing at a double-digit rate, and I anticipate that momentum will continue. More Indian companies will move up the value chain - not just making basic kits, but developing sophisticated molecular diagnostics, AI-driven testing tools, and even exporting lab automation systems. The Promotion of Research and Innovation in the Pharma-MedTech Sector (PRIP) will catalyse increased spending on R&D, and we anticipate the resultant positive outcomes in the years to come. With initiatives like the PLI scheme creating “global champion” IVD firms out of India, we will have a stronger manufacturing base and innovation pipeline.
Domestically, diagnostics will penetrate deeper: I expect a laboratory or point-of-care facility in every small town, enabled by cost-effective tech developed here. From a global perspective, India's reputation as an exporter of reliable diagnostic products will be solidified – we're already seeing our export growth outpace imports. This trend should enable us to become net exporters by the end of the decade. As ADMI President, I plan to push for all the necessary enablers to realise this vision. The future is one where Indian-developed diagnostic tests and devices are used worldwide, and every citizen has access to timely and accurate tests at home. In short, the outlook is of robust growth and innovation, with India's diagnostics sector attaining a position of global leadership while saving millions of lives through early and precise disease detection.
How big and diverse is the IVD market in India?
Bu hikaye BioSpectrum Asia dergisinin BioSpectrum Asia Nov 2025 baskısından alınmıştır.
Binlerce özenle seçilmiş premium hikayeye ve 9.000'den fazla dergi ve gazeteye erişmek için Magzter GOLD'a abone olun.
Zaten abone misiniz? Oturum aç
BioSpectrum Asia'den DAHA FAZLA HİKAYE
BioSpectrum Asia
"The next 5-years will see mRNA science evolve beyond infectious disease"
A new survey from Moderna Singapore reveals persistent vaccine hesitancy among older adults in Singapore, even as international travel and year-end gatherings increase the urgency of protection. The findings point to clear opportunities to strengthen public health, including empowering healthcare professionals as trusted messengers and promoting co-administration of vaccines.
4 mins
BioSpectrum Asia Dec 2025
BioSpectrum Asia
No Funding No Vax for TB?
The World Health Organization (WHO)'s latest updates on tuberculosis (TB) released on November 12 reveal significant progress in diagnosis, treatment, and political commitment, but also expose deep vulnerabilities—especially in the South-East Asia Region (SEARO)—related to funding gaps and the uncertain future of novel TB vaccines. SEARO remains the global epicentre of the TB epidemic, carrying more than 45 per cent of the world's TB incidence despite representing only a quarter of the global population.
2 mins
BioSpectrum Asia Dec 2025
BioSpectrum Asia
Australia builds tailored heart pump to transform heart failure care
Despite making up half of the 64 million people living with heart failure, patients with this common form have no access to heart pump treatments and are left with only medication or palliative care.
1 min
BioSpectrum Asia Dec 2025
BioSpectrum Asia
Clinical Research Trends 2026: Hybrid DCTs Set for Surge as Innovation Outpaces Regulatory Hurdles
APAC's openness to innovation, combined with its large population and low trial density, creates strong potential for expanding decentralised clinical trials (DCTs), especially for patients with limited trial access. While regulatory diversity and operational challenges will continue to hinder fully decentralised models, the region is expected to adopt more digital technologies in clinical research. As a result, hybrid DCTs will keep gaining traction, and effective management of digitally collected data will remain a central focus for data science teams.
4 mins
BioSpectrum Asia Dec 2025
BioSpectrum Asia
CSL Seqirus to localise advanced influenza vaccine manufacturing in Saudi Arabia
Australia-based CSL Seqirus and Vaccine Industrial Company have signed a Memorandum of Understanding with the Ministry of Health of Saudi Arabia to enhance the biotechnology sector by accessing advanced cellbased seasonal and pandemic influenza vaccines and localising manufacturing in Saudi Arabia.
1 min
BioSpectrum Asia Dec 2025
BioSpectrum Asia
How Sponsors Could Gain Advantage by Embracing Dose Optimisation in Asia by 2026
In 2026, oncology drug development in Asia may move away from the historical maximum tolerated dose (MTD) paradigm toward evidence-based dose optimisation. Sponsors might consider adopting strategies similar to the FDA's Project Optimus, which emphasises selecting doses that balance efficacy and safety rather than relying solely on toxicity thresholds. Doing so could improve patient outcomes and position companies favourably as regulatory expectations evolve.
1 mins
BioSpectrum Asia Dec 2025
BioSpectrum Asia
Fujifilm launches joint research with National Cancer Center in Japan
Fujifilm Corporation has signed a joint research agreement with the National Cancer Center Japan, a Tokyo-based national institution recognised for its leadership in cancer care and research.
1 min
BioSpectrum Asia Dec 2025
BioSpectrum Asia
Monash spinout RAGE Biotech secures $29 M to advance next-generation RNA therapeutics
Australia's Monash University spinout RAGE Biotech has raised $29 million in Series A funding, marking a major step toward translating RNA-based therapeutics for chronic inflammatory disease into the clinic.
1 min
BioSpectrum Asia Dec 2025
BioSpectrum Asia
Submitting clinical data to the FDA and PDMA: An efficient and compliant approach
In both the US and Japan, regulators provide an extensive set of resources detailing the rules and specifications governing submissions for marketing approval of new drugs and biologics. Fortunately, despite some differences, the regulations concerning clinical data have a surprising amount in common. It is possible that with a solid understanding of the requirements and an adherence to best practices, sponsors can develop some of the same material for submission to both countries.
2 mins
BioSpectrum Asia Dec 2025
BioSpectrum Asia
Regenerative medicines and microbiome health are emerging as exciting frontiers, with Australian companies and researchers pushing into new therapeutic approaches
After more than a year at the helm of AusBiotech, CEO Rebekah Cassidy reflects on her early priorities and the organisation’s ambitions as Australia accelerates its position in the global life sciences economy. In an email interaction on the sidelines of AusBiotech 2025, she highlights the country's progress in mRNA, cell and gene therapy, and radiopharmaceuticals, outlines emerging areas of momentum, and discusses how new partnerships and MoUs are strengthening collaboration across the biotech ecosystem. Rebekah also outlines how AusBiotech is preparing Australia for a more competitive and connected global life sciences economy and the strategic priorities shaping AusBiotech’s next chapter. Edited excerpts:
7 mins
BioSpectrum Asia Dec 2025
Listen
Translate
Change font size

